Early-Stage trial tests immune therapy for untreated lymphoma
NCT ID NCT03498612
Summary
This study tested whether pembrolizumab, an immunotherapy drug, could help control certain slow-growing B-cell lymphomas in people who hadn't yet received any treatment. The goal was to see if boosting the body's immune system could attack the cancer cells. The trial was stopped early after enrolling only 9 participants, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.